T1	Participants 384 410	subjects with FXS (n = 49)
T2	Participants 810 821	CX516 group
T3	Participants 826 835	1 subject
T4	Participants 1205 1219	FXS population
T5	Participants 1439 1444	CX516
T6	Participants 1053 1075	CX516-treated subjects
T7	Participants 1262 1276	Adult subjects
